Showing 3861-3870 of 10742 results for "".
- Researchers Recommend Refined Trial Design for Pediatric Vitiligo JAK Studieshttps://practicaldermatology.com/news/letter-highlights-trial-design-considerations-in-pediatric-vitiligo/2487858/Correspondence in the Journal of the American Academy of Dermatology asked for caution when interpreting findings from a recent trial evaluating oral Janus kinase (JAK) inhibitors in combination with 308-nm excimer laser th
- Study: One-Third of Pemphigus Cases Deviate From Classic Desmoglein Compensation Modelhttps://practicaldermatology.com/news/study-one-third-of-pemphigus-cases-deviate-from-classic-desmoglein-compensation-model/2487700/
- Laser Speckle Imaging Shows Promise for Objective Rosacea Assessment: Analysishttps://practicaldermatology.com/news/laser-speckle-imaging-shows-promise-for-objective-rosacea-assessment-analysis/2487680/
- Letter Questions Strength of Evidence Linking Hair Relaxers to Uterine Cancerhttps://practicaldermatology.com/news/letter-questions-strength-of-evidence-linking-hair-relaxers-to-uterine-cancer/2487618/A recently published Letter to the Editor in the Journal of Drugs in Dermatology urged clinicians to interpret the growing body of research examining chemical hair relaxers and uterine cancer with caution, arguing that important methodological limitations prevent current evidence from es
- Low Infection Risk Across Psoriasis Biologics Reported in Real-World Studyhttps://practicaldermatology.com/news/low-infection-risk-across-psoriasis-biologics-reported-in-real-world-study/2487541/A large real-world analysis published in the Journal of the American Academy of Dermatology indicates biologic therapies for psoriasis are associated with low overall infection risk, with ustekinumab and interleukin (IL)-23
- FDA Approves OTC Switch for Galderma’s Differin Epiduo Acne Gelhttps://practicaldermatology.com/news/fda-approves-otc-switch-for-galdermas-differin-epiduo-acne-gel/2487203/The US Food and Drug Administration (FDA) has approved Galderma’s Differin Epiduo Acne Gel (adapalene 0.1% and benzoyl peroxide 2.5%) for over-the-counter (OTC) use in patients aged 12 years and older, marking a notable prescription-to-OTC transition in acne therap
- Topical NAC Plus Doxycycline Shows Benefit in Moderate Acnehttps://practicaldermatology.com/news/topical-nac-plus-doxycycline-shows-benefit-in-moderate-acne/2486948/Topical N-acetylcysteine (NAC) plus doxycycline was associated with greater improvement than benzoyl peroxide (BPO) plus doxycycline in patients
- Study: GLP-1 Linked with PASI Reductionshttps://practicaldermatology.com/news/early-evidence-links-glp-1-therapy-to-pasi-reductions/2486929/Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are gaining attention as a potential adjunctive therapy in psoriasis, according to a new review from the National Psoriasis Foundation Medical Board published in JAMA Dermatol
- TRuE-AD4: Ruxolitinib Cream Improves QoL and Sleep in Moderate ADhttps://practicaldermatology.com/news/true-ad4-ruxolitinib-cream-improves-qol-and-sleep-in-moderate-ad/2486434/Ruxolitinib cream 1.5% demonstrated consistent improvements in patient-reported outcomes among adults with moderate atopic dermatitis (AD) who previously had inadequate response, intolerance, or contraindications to topical corticosteroids (TCS) and topical calcine
- EMA Panel Backs Baricitinib for Adolescents With Severe Alopecia Areatahttps://practicaldermatology.com/news/ema-panel-backs-baricitinib-for-adolescents-with-severe-alopecia-areata/2485850/The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of baricitinib (Olumiant, Eli Lilly and Company), a once-daily oral Janus kinase (JAK) inhibitor, for adolescents aged 12 to yo